Ventyx Biosciences Stock News

Data from the recent Phase 2 study position Ventyx's NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson's disease Topline data from Phase 2 study of VTX2735 in patients with recurrent pericarditi...

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors October 22, 2025 4:30 PM EDT Company Participants Alex Schwartz Raju Mohan - Founder, CEO, President & Director Mark Forman Roy Gonzales - Senior VP of Finance and Principal Financial & Accounting Officer Conference Call Participants Antonio Abbate Peter Libby Lin Ts...

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L 1 Statistically significant reductions in Lp(a) and liver inflammation No effect o...

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences: 2025 Wells Fargo ...

Ventyx Biosciences (VTYX -6.72%), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and neurodegenerative diseases, released its second-quarter 2025 results on August 7, 2025. EPS (GAAP) was $0.38, which exceeded the analyst consensus estimate of $(0.47) GAAP.

Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson's disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 Cash...

The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Con...